Orphazyme A/S Profit Margin

Orphazyme A/S posts a profit margin of -485.57% as of June 2026. That is below the Healthcare sector average of 9.71%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a profit margin near 9.71% is typical. Orphazyme A/S's -485.57% is lower that level. That is roughly 5102.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Orphazyme A/S's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -485.57% as of June 2026; use YoY and peer views to separate noise from signal.

Context for ORPH's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.71%), and (3) consistency with growth and profitability. This page covers the first two; Orphazyme A/S's other metric pages and overview cover the third.

Judging Orphazyme A/S against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in profit margin easier to interpret. Start with -485.57% here, then scan peer and history charts to see if the gap is persistent.